• Join
  • Login
  • Contact

Search abstracts

Biosimilar infliximab: short-term efficacy and safety following switch from originator

  • In: Oral presentation on Tuesday, 12 September 2017, 14:30-17:30
  • At: Seoul (South Korea) (2017)
  • Type: Presentation
  • By: MATULUKO, Ayodeji (University College London, School of Pharmacy, London, UK)
  • Co-author(s): Ayodeji Benedicta Matuluko: School of Pharmacy, University College London, United Kingdom
    Natalie Bidad: Department of Practice and Policy, School of Pharmacy, University College London, United Kingdom
    Scott Mercer: Immunotherapy (Rheumatology, Dermatology, Allergy), Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
  • Abstract:


    A retrospective/prospective evaluation with a convenience sample of 28 adults who had switched from originator to biosimilar infliximab, was conducted in a rheumatology clinic in London, United Kingdom. Data from patients’ records was collected from May to July 2016, including demographic characteristics, markers of clinical response and


  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses